MedTrace Logo

A Study to Evaluate the Efficacy and Safety of Add-on Therapy of Wuling Capsule in Epilepsy Patients With Depression

NCT01125241 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 104

Last updated 2014-09-17

No results posted yet for this study

Summary

The main purpose of this study is to determine the effects of add-on therapy of wuling capsule on depressive symptoms in patients with comorbidity of epilepsy and depression, to evaluate its influences on the frequency and severity of seizures, and to observe its effects on patients' sleeping condition, quality of life.

Conditions

Interventions

DRUG

wuling capsule

orally, three tablets each time,three times a day

DRUG

placebo of wuling capsule

orally, three tablets each time and three times a day

Sponsors & Collaborators

  • Shanghai Wu Mengchao Medical Foundation

    collaborator UNKNOWN

  • Shanghai Ankang Pharmaceutical Co.,LTD

    collaborator UNKNOWN

  • Shanghai Zhongshan Hospital

    lead OTHER

Principal Investigators

  • Wang Xin, MD · Fudan University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-09-30
Primary Completion
2013-08-31
Completion
2013-08-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01125241 on ClinicalTrials.gov